Mezzopram

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mezzopram

Quick Facts

Property Description
Active ingredient Omeprazole (often as Omeprazole magnesium)
Form Gastro-resistant tablet, Delayed-release capsule
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Reducing gastric acid secretion
Origin Synthetic substituted benzimidazole

What Type of Medicine is Mezzopram (Omeprazole)?

Mezzopram is a potent antisecretory compound that belongs to the Proton Pump Inhibitor (PPI) pharmacological class, a category recognized for its efficacy in controlling stomach acid. The drug's therapeutic action is delivered by its single active ingredient, Omeprazole or its salt, Omeprazole magnesium, which is often available as both a prescription-only and over-the-counter product depending on the specific formulation. Omeprazole is a synthetic substituted benzimidazole compound that functions as a prodrug. Its classification as a PPI means it acts on the final stage of acid creation, offering a means of acid control.


Composition and Delivery Form (Gastro-Resistant Type)

The medication is a single-ingredient product administered via the oral route, typically supplied as a gastro-resistant tablet or delayed-release capsule. This specialized coating is crucial because the active component, Omeprazole, is highly sensitive to acid and would be destroyed by the stomach's own environment before absorption could occur. This gastro-resistant matrix is designed to ensure the medication bypasses the stomach intact and allows the Omeprazole (often a racemic mixture) to be properly absorbed in the small intestine. This delayed-release formulation is a distinctive feature necessary for the drug's systemic action.


General Purpose: Reducing Gastric Acid Secretion

The general purpose of Mezzopram is the sustained suppression of gastric acid secretion, which mitigates the discomfort and irritation caused by excessive acid levels in the upper digestive tract. For instance, it is a typical therapeutic approach used when there is a need to lower the amount of acid the stomach produces over an extended period. As a Proton Pump Inhibitor, the drug achieves this by selectively and irreversibly inhibiting the H^+/K^+-ATPase enzyme system—the gastric proton pump. This action ensures the stomach’s pH is elevated, thereby providing relief and allowing irritated tissues to begin healing.

Regulatory References

  1. electronic Medicines Compendium, MHRA

What side effects are possible with Mezzopram?

Possible side effects and safety information

The safety profile of Mezzopram (Omeprazole) is detailed in regulatory documents, classifying possible adverse reactions by frequency and physiological system. This information is non-instructional and strictly based on official labeling.

Frequency-Classified Adverse Reactions

The most frequently documented effects are classified as Common, occurring in the Gastrointestinal system, including abdominal pain, flatulence, diarrhea, constipation, nausea, and vomiting. Headache is also a common reaction. Effects classified as Uncommon include insomnia, dizziness, and certain dermatological reactions such as rash and pruritus. Rare documented reactions involve more severe systemic effects such as acute Interstitial Nephritis and severe hypersensitivity like Angioedema.

Serious Adverse Reactions and Long-Term Safety Patterns

Official labeling documents specific rare but Very Rare serious adverse reactions, including severe cutaneous reactions (e.g., Stevens-Johnson Syndrome) and severe blood disorders (e.g., Agranulocytosis).

Safety statements linked to long-term use and prolonged exposure are explicitly included in the regulatory profile. Use for a year or longer is associated with an increased risk for bone fractures of the hip, wrist, or spine. Additionally, long-term therapy (typically three months or more) is linked to the development of Hypomagnesaemia (low magnesium levels). The regulatory documents note that diminished anti-platelet activity of Clopidogrel is a safety consequence of concomitant use. Safety constraints also include an increased risk of Gastrointestinal infections (such as Clostridium difficile-associated diarrhea).

Specific considerations exist for patients with Hepatic Impairment, where clearance is reduced, and there is a documented risk of encephalopathy in those with pre-existing severe liver disease.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mezzopram (Omeprazole) overdosage is defined by a cluster of documented clinical manifestations and mandatory emergency actions. Manifestations reported in cases of acute overdosage, involving single doses up to 900 mg, have included neurological effects such as confusion, drowsiness, headache, and blurred vision. Other reported signs encompass tachycardia (increased heart rate), nausea, flushing, diaphoresis (increased sweating), and dry mouth. Official prescribing information states that these symptoms were transient and confirms that no serious clinical outcome has been reported in association with omeprazole overdosage.

For any suspected overdosage, immediate medical intervention is mandated by the regulator. Individuals must seek immediate medical attention and contact a Poison Control Center right away, even if symptoms appear mild.

The officially described management dictates that treatment should be strictly symptomatic and supportive. This is necessary because no specific antidote for omeprazole overdosage is known. Additionally, the regulatory documents note the procedural constraint that Omeprazole is extensively protein bound and is therefore not readily dialyzable.

Therapeutic Uses of Mezzopram

Quick Facts

Condition
Addressing active duodenal and gastric ulcers
Promoting healing of erosive esophagitis
Managing symptoms of gastroesophageal reflux disease (GERD)
Used with antibiotics to help eradicate Helicobacter pylori
Long-term management of hypersecretory conditions (e.g., Zollinger-Ellison syndrome)

Mezzopram is a medication used for managing conditions associated with excess stomach acid. The therapeutic focus of this agent is primarily in the gastrointestinal tract, where it helps address damage and symptoms related to acid-related disorders.

Its uses include the short-term treatment of active duodenal and gastric ulcers. The medication is also indicated for promoting the healing of tissue damage in the esophagus (erosive esophagitis) that is associated with acid reflux. Furthermore, it is used for the maintenance of healing of this specific esophageal damage.

For patients presenting with symptoms of gastroesophageal reflux disease (GERD), Mezzopram provides an option to help manage frequent heartburn and other associated discomforts. In cases of peptic ulcer disease confirmed to be related to the Helicobacter pylori bacterium, this agent is a component of the combination therapy used for bacterial eradication.

Finally, the medication is used for the long-term management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where the stomach generates abnormally high acid levels.

Regulatory References

  1. NIH MedlinePlus guidance on omeprazole

Eligibility and Restrictions for Use

Who Can and Cannot Use Mezzopram?

This section summarizes the official eligibility rules for using Mezzopram (Omeprazole) as defined by governmental regulatory documents.


Contraindicated Populations

Mezzopram is strictly contraindicated and must not be used in two primary patient groups:

  • Patients with known hypersensitivity or allergy to omeprazole, to the substituted benzimidazoles drug class, or to any component of the formulation.
  • Patients taking the antiretroviral agent nelfinavir, as co-administration is prohibited by regulatory labels.

Age and Organ Function Eligibility

Population Group Regulatory Status
Infants (< 1 year old) Use is not established as safety and efficacy data are insufficient for this age group.
Adults and Older Adults Fully eligible; no dose adjustment is typically required for older adults or those with renal impairment.
Hepatic Impairment Eligible, but use may require consideration of a lower daily dose due to altered drug clearance.

Pregnancy and Lactation

Omeprazole can be used during pregnancy based on epidemiological studies. It is also generally considered acceptable during lactation, though the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mezzopram (Omeprazole) has officially documented interactions primarily stemming from two mechanistic classifications: the inhibition of the CYP2C19 liver enzyme and the effect of sustained gastric pH elevation.

Co-administration with the antiretroviral agents Rilpivirine and Nelfinavir is classified as a contraindication in regulatory documents due to the significant reduction in the plasma exposure of these medicines.

Pharmacokinetic and Pharmacodynamic Interactions

As a moderate CYP2C19 inhibitor, Omeprazole alters the metabolism of co-administered drugs like Warfarin, Diazepam, and Phenytoin, potentially increasing their plasma concentrations and effects. This inhibition is also documented to diminish the anti-platelet effect of Clopidogrel by impairing its metabolic activation, which is a key restriction.

Exposure and Timing Restrictions

Elevation of gastric pH reduces the absorption and subsequent plasma levels of medicines that require an acidic environment, including antifungals such as Ketoconazole and Itraconazole. Conversely, this change may increase the exposure of Digoxin and the immunosuppressant Tacrolimus, necessitating official concentration monitoring. Furthermore, Omeprazole use must be temporarily stopped prior to certain laboratory tests, such as assessing Chromogranin A (CgA) levels, to prevent diagnostic interference. Strong enzyme inducers like Rifampin and St. John's Wort may reduce Omeprazole concentrations.

Mechanism of Action

How Mezzopram Works: Mechanism of Action

Mezzopram (Omeprazole) is an inhibitor that acts on the H^+/ K^+-ATPase, the enzyme responsible for the final stage of acid production within the stomach's acid-secreting parietal cells.


Irreversible Inhibition of the Gastric Proton Pump

The drug functions as an acid-activated prodrug that, after conversion in the acidic cellular environment, forms a permanent covalent bond with specific amino acid residues on the exposed surface of the H^+/ K^+-ATPase, known as the gastric proton pump. This irreversible binding halts the transport of hydrogen ions ( H^+) into the stomach lumen, thus inhibiting acid secretion by the final transport mechanism, independent of upstream stimuli.


Enzyme Turnover Dictates Sustained Physiological Effect

The prolonged duration of the drug’s antisecretory action is determined by the slow biological process of enzyme turnover. Since the inhibition is permanent, the parietal cell must synthesize entirely new proton pump enzymes to restore acid production. This mechanism results in a prolonged duration of pH elevation that persists for significantly longer than the drug’s presence in the plasma.


Selectivity for the Active Enzyme State

The inhibitory action is most effective against active, secreting proton pumps that are fully translocated to the cell surface. This mechanistic selectivity requires the progressive inactivation of pumps over time, leading to a gradual achievement of the maximal physiological effect, typically reached after several days of continuous treatment.

Dosage and Administration Information

How Mezzopram is Used

Mezzopram (Omeprazole) is administered exclusively via the oral route as a delayed-release capsule, tablet, or oral suspension. The administration procedure is designed to ensure the medication bypasses stomach acid for proper systemic absorption. The medication must be taken before eating, ideally in the morning.

Dosing and Frequency Patterns

The dosage and frequency are determined by the specific acid-related condition being managed. The standard adult administration schedule for many indications, including active ulcers and erosive esophagitis, is once daily, with doses typically ranging from 20 mg to 40 mg.

Condition Typical Adult Dosing Regimen Frequency Pattern
Active Gastric Ulcer, Erosive Esophagitis (Healing) 40 mg Once Daily (for 4 to 8 weeks)
H. pylori Eradication (Triple Therapy) 20 mg Twice Daily (for 10 days)
Zollinger-Ellison Syndrome Initial 60 mg daily; up to 360 mg/day Divided Doses (for doses >80 mg/day)

For most short-term treatments, such as symptomatic gastroesophageal reflux disease (GERD), the duration is limited to approximately four weeks. Long-term use is typically reserved for maintenance therapy or chronic hypersecretory states, such as Zollinger-Ellison Syndrome.

Administration Conditions and Adjustments

The delayed-release capsules or tablets must be swallowed whole with water; they should not be crushed or chewed, as this compromises the essential gastro-resistant coating. If the patient is unable to swallow the capsule, the contents may be mixed with a tablespoon of applesauce and swallowed immediately. While no dose adjustment is generally necessary for patients with renal impairment, a lower daily dose, such as 10 mg to 20 mg, may be considered sufficient for patients with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mezzopram

Evidence for Treating Stomach and Duodenal Ulcers

Research explored patient populations diagnosed with active ulcers in the stomach (gastric) and the first part of the small intestine (duodenum). Researchers used short-term Randomized Controlled Trials (RCTs) and systematic meta-analyses to examine the measured change in ulcer status, focusing on endoscopic confirmation and patient-reported outcomes. Studies reported documented measurements of ulcer status from endoscopy at specific time points across comparison groups. Research highlights changes measured during the acute treatment period, contributing to understanding short-term symptom patterns.

What remains uncertain is the long-term characterization of these conditions. Since most definitive trials focus on the acute treatment phase, follow-up durations were limited for long-term monitoring. Existing studies provide limited insight into how these outcomes relate to specific comorbidity-defined populations.


Research on Esophageal Healing and Reflux Symptoms (GERD)

Research has explored Mezzopram in the context of conditions characterized by fluctuating manifestations, such as Gastroesophageal Reflux Disease (GERD). For patients with visible tissue damage (Erosive Esophagitis, EE), RCTs and long-term observational cohorts were used to measure the outcomes linked to inflammatory or irritative states. Multiple studies reported measurements of EE healing rates at the 4- and 8-week time points across comparison groups. Findings described measurements tracking periods in maintenance trials where the recurrence of erosions was not observed.

While data on observed changes in recurrence were tracked over intermediate durations, long-term effects are not fully established. Outcomes beyond one year often rely on observational study designs rather than controlled trials. Evidence quality varies across studies when comparing reported measurements due to the heterogeneity (variability) in trial definitions for symptom resolution.


Evidence When Used for H. Pylori Eradication

Research examined Mezzopram as a component in combination therapy alongside antibiotics, exploring the H. pylori clearance rate in patients with this infection. Studies observed and tracked the incidence of ulcer relapse in populations of adults and children aged four and older with confirmed infection. Reported clearance success rates may appear mixed and exhibit variability, which is often attributed to the evolving local patterns of bacterial antibiotic resistance. Data for certain groups remain insufficient, and evidence is limited regarding the outcomes of these regimens in patients with complex medication usage profiles or adherence challenges.


Studies on Rare and Complex Hypersecretory Conditions

For rare disorders such as Zollinger-Ellison Syndrome (ZES), the evidence is derived primarily from case series and long-term observational follow-up studies rather than large-scale RCTs. Outcomes monitored include measurements of reduced gastric acid output and changes in systemic symptoms. Sample sizes were modest and limited due to the rarity of the conditions studied. Comparative evidence is lacking, and results apply only to the specialized populations studied in these observational settings.

Key Studies & References

  1. Omeprazole: Label - DailyMed (FDA-approved Prescribing Information)
  2. Omeprazole: MedlinePlus Drug Information (Patient-facing overview of uses and evidence)
  3. Stewardship of Proton Pump Inhibitors: Considerations for Use and Deprescribing (Review of indications and long-term use patterns)

Frequently Asked Questions (FAQ)

Common questions about Mezzopram (FAQ)


Q: How quickly does Mezzopram start working?

Regulatory documents state that the inhibitory effects on stomach acid production begin rapidly, typically within one hour after administration. The medication typically reaches its maximum effect on acid reduction within two hours of taking the dose.


Q: Is Mezzopram safe to take long-term?

Official product information describes potential safety considerations linked to long-term use, defined as typically over one year. These include an increased risk of bone fractures (hip, wrist, spine), the development of low magnesium levels (hypomagnesemia), and vitamin B12 deficiency.


Q: Does Mezzopram make you tired or drowsy?

Official drug labeling reports that drowsiness and fatigue have been observed as common to uncommon side effects in patients taking Mezzopram.


Q: What are the signs of an allergic reaction to Mezzopram?

The official Patient Medication Guide describes signs of a severe allergic reaction that warrant immediate medical evaluation. These signs include difficulty breathing, swelling of the face, lips, tongue, or throat, or the appearance of hives.


Q: What kind of research has been done on Mezzopram in children?

Regulatory evidence indicates that safety and effectiveness have been established for the short-term treatment of certain conditions in children aged one month and older. These conditions include Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE).


Q: Is Mezzopram a generic or a brand name medicine?

Omeprazole is the name of the active ingredient and is widely available as a generic medicine. It is also available in various formulations under different brand names.


Q: What is the maximum duration of treatment with Mezzopram studied in trials?

According to official labeling, the effectiveness for treating Erosive Esophagitis (EE) in clinical trials has not been established for use longer than 8 weeks. Official documentation notes that an additional 4 weeks may be considered in some circumstances.


Q: Is Mezzopram approved by the FDA?

Yes, the omeprazole products that comprise Mezzopram are approved by the U.S. Food and Drug Administration (FDA) for their intended uses.


Q: Can I use Mezzopram if I am trying to conceive?

Regulatory information reports that animal studies showed no adverse effects on fertility. Since reproductive data in humans should always be reviewed carefully, consulting a health professional is advised when planning pregnancy.


Q: What are the chances of experiencing a serious side effect from Mezzopram?

Official clinical trial data categorizes adverse reactions by frequency. The majority of reported side effects are common and considered generally mild, while serious adverse reactions are typically classified as uncommon or rare (such as occurring in less than 0.1% of patients).


Q: What are the general expectations for someone starting Mezzopram?

The drug is intended to provide sustained acid suppression by reducing the amount of acid the stomach produces. The maximum acid-blocking effects are reached after several days of continuous daily use, typically by the fourth day.


Q: Can Mezzopram cause weight gain?

Weight increase has been reported in post-marketing experience. Official safety documents classify this as a very rare side effect, occurring in less than 0.01% of patients.


Q: Are there any specific foods or drinks to avoid while taking Mezzopram?

Official administration instructions recommend taking the drug before a meal. While no specific foods are strictly restricted, excessive alcohol consumption may stimulate acid production and could potentially counteract the drug's intended effect.


Q: What happens if I forget a dose of Mezzopram?

Official administration guidance specifies that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should not be taken. Regulatory guidance also specifies that two doses should not be taken at one time.


Q: Is Mezzopram considered a controlled substance?

No, omeprazole is not listed as a controlled substance under the federal Controlled Substances Act.


Q: Does taking Mezzopram affect my ability to drive?

Official safety information states that uncommon side effects such as dizziness and visual disturbances have been reported. These effects may potentially impair the ability to drive or operate heavy machinery.


Q: Does Mezzopram interact with birth control pills?

Clinical studies have examined the drug’s potential for interaction with combined hormonal contraceptives. Data indicate that omeprazole, at commonly prescribed doses, showed no measurable effect on circulating levels of estradiol or testosterone.


Q: Is it true that Mezzopram causes dry mouth?

Dry mouth has been reported as an adverse event in post-marketing reports. The official documentation notes that the incidence rate of dry mouth is currently unknown.


Q: What information is available about stopping Mezzopram?

The official Patient Medication Guide emphasizes the importance of consulting a healthcare provider before changing or stopping the medication.


Q: Can people with heart conditions use Mezzopram?

Regulatory documents include a specific warning regarding concomitant use with the anti-platelet drug Clopidogrel (a medicine often taken by people with heart conditions). This is because omeprazole may reduce the anti-platelet effect of Clopidogrel.


Q: What does 'contraindication' mean in relation to Mezzopram?

A contraindication is an official statement that the drug should not be used in specific patient groups. For Mezzopram, this applies to patients with a known hypersensitivity (allergy) to any component of the formulation or to similar drugs (substituted benzimidazoles).


Q: Is Mezzopram known to cause dependence?

The regulatory label states that the drug has no known abuse potential or dependence risk. However, official information notes that stopping treatment may result in a temporary return of symptoms due to a physiological effect called rebound acid hypersecretion.


Q: Is there a patient brochure or official information sheet for Mezzopram?

Yes, a specific document called a Medication Guide is required to be dispensed with the prescription. This guide is designed to inform patients about the safe and effective use of the drug.


Q: Can using Mezzopram affect my mood?

Official safety documents list certain effects related to mood and psychiatric function. Confusion and agitation have been reported as uncommon side effects, while more severe effects like depression and hallucinations are listed as rare.

How should Mezzopram be stored and disposed of?

The official regulatory label for Mezzopram (omeprazole) defines specific storage and handling requirements essential for maintaining product stability and quality.


Storage Conditions

Mezzopram must be stored at a temperature not exceeding 25°C and requires protection from moisture. The medicine must be kept in its original container and, if supplied in a bottle, the container should be kept tightly closed to maintain environmental protection.


Stability and Safety

If the original HDPE container is first opened, the product has an in-use shelf life of 6 months. As a standard safety measure, this medication must be stored out of the sight and reach of children.


Disposal

Any unused or expired product must be disposed of according to local requirements for pharmaceutical waste handling. Regulatory documents generally state no special hazardous waste requirements for its disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mezzopram found in:

A-Z Index: